This Profile in Personalized Medicine highlights Stacy Hightower. She is the lead marketer and compounding compliance officer for Las Colinas Pharmacy in Irving, Texas, owned by Jim and Jan Hrncir. They have been a proud PCCA member since 1990. Our new 2023 profiles ask pharmacy compounders how they incorporate PCCA’s Principles into their pharmacies.

Polycystic ovary syndrome (PCOS) is the most prevalent hormonal disorder affecting women of reproductive age across the globe and the CDC estimates PCOS may be one of the most common causes of infertility. Learn how to help patients with PCOS.

Genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy, is common among menopausal women. Learn more about GSM, relevant hormones and the importance of choosing the right base for compounding preparations.

Scientists detected evidence of DNA methylation abnormalities in patients with autism spectrum disorder (ASD). Learn how compounders may potentially help ASD patients with methylcobalamin preparations.

Learn why methylene blue, synthesized in 1876 as a dye for the textile industry, has rekindled interest for therapeutic use in diseases.

Read why Kayla Valigura, PharmD candidate and 2022 PCCA Institute Scholarship award winner, wants your help in acting on something near and dear to her heart.

PCCA's Matt Martin and Melissa Merrell Rhoads provide guidance and examples to help you determine API calculations in your compounding pharmacy.

This Profile in Personalized Medicine highlights Stephanie Yang, owner and co-founder of Accent Wellness Compounding Pharmacy in Subang Jaya, Selangor, Malaysia. She has been a proud PCCA member since 2011. Our new 2023 profiles ask pharmacy compounders how they incorporate PCCA’s Principles into their pharmacies.

We’re reviewing the distinctions between SuspendIt and SuspendIt Anhydrous, as well as how revisions to USP Chapter 795 will guide beyond use dates (BUDs) for aqueous and nonaqueous oral dosage forms.

FDA’s Guidance for Industry (GFI) on compounding for animals using bulk drug substances will be used in FDA inspections starting on April 1, 2023. Read the top five potential impacts on compounding for animal patients.